PerspectivePhotodynamic therapy for age-related macular degeneration: a candid appraisal☆
References (2)
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfintwo-year results of 2 randomized clinical trials—TAP report no. 2
Arch Ophthalmol
(2001)Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degenerationtwo-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin in Photodynamic Therapy report 2
Am J Ophthalmol
(2001)
Cited by (15)
Combination of pigment epithelium derived factor with anti-vascular endothelial growth factor therapy protects the neuroretina from ischemic damage
2022, Biomedicine and PharmacotherapyCitation Excerpt :Anti-VEGF therapy is effective in inhibiting VEGF and reversing neovascularization, and it also inhibits physiological revascularization [4–6]. Several other treatments such as retinal laser photocoagulation, transpupillary thermotherapy and photodynamic therapy are used to treat ischemia-related retinal diseases, but these approaches are damaging to the retina and not always effective [7,8]. Retinal neurons, such as retinal photoreceptor cells and retinal ganglion cells (RGCs) are responsible for the transmission of the visual information process to the brain and are vulnerable to ischemia [9].
Preclinical photodynamic therapy research in Spain 3: Localization of photosensitizers and mechanisms of cell death in vitro
2009, Journal of Porphyrins and PhthalocyaninesA study of the vitreoretinal interface in patients with age-related macular degeneration
2016, Arquivos Brasileiros de Oftalmologia
- ☆
Doctor Lewis was an Investigator in the TAP and VIP studies, and travel funds were provided by Novartis to attend the study meetings. Doctor Sternberg was an Investigator in the VIP, VOH, and VER studies. Neither Dr. Sternberg nor Dr. Lewis has any financial interest or any conflict of interest.